These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38713052)

  • 101. EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.
    Voutsadakis IA
    Curr Issues Mol Biol; 2023 Jul; 45(7):6040-6054. PubMed ID: 37504297
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
    Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
    Voutsadakis IA
    Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
    [No Abstract]   [Full Text] [Related]  

  • 104. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer.
    Nishijima TF; Kardos J; Chai S; Smith CC; Bortone DS; Selitsky SR; Parker JS; Sanoff HK; Lee MS; Vincent BG
    JCO Precis Oncol; 2017 Nov; 1():1-10. PubMed ID: 35172495
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Nuclear staining of claudin-18 is a new immunohistochemical marker for diagnosing intramucosal well-differentiated gastric adenocarcinoma.
    Takahashi Y; Tsutsumi Y; Takeuchi C; Shiogama K; Mizutani Y; Inada KI; Yamamichi N; Koike K
    Pathol Int; 2020 Sep; 70(9):644-652. PubMed ID: 32623829
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Claudin 18.2 as a novel therapeutic target.
    Nakayama I; Qi C; Chen Y; Nakamura Y; Shen L; Shitara K
    Nat Rev Clin Oncol; 2024 May; 21(5):354-369. PubMed ID: 38503878
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract][Full Text] [Related]  

  • 108. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.
    Voutsadakis IA
    Crit Rev Oncol Hematol; 2023 Jun; 186():103987. PubMed ID: 37059275
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Claudin-1, A Double-Edged Sword in Cancer.
    Bhat AA; Syed N; Therachiyil L; Nisar S; Hashem S; Macha MA; Yadav SK; Krishnankutty R; Muralitharan S; Al-Naemi H; Bagga P; Reddy R; Dhawan P; Akobeng A; Uddin S; Frenneaux MP; El-Rifai W; Haris M
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952355
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials.
    Kyuno D; Takasawa A; Takasawa K; Ono Y; Aoyama T; Magara K; Nakamori Y; Takemasa I; Osanai M
    Tissue Barriers; 2022 Jan; 10(1):1967080. PubMed ID: 34486479
    [TBL] [Abstract][Full Text] [Related]  

  • 111. The role of claudin-4 in the development of gastric cancer.
    Liu W; Li M
    Scand J Gastroenterol; 2020 Sep; 55(9):1072-1078. PubMed ID: 32715822
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies.
    Voutsadakis IA
    Tissue Barriers; 2024 May; ():2348852. PubMed ID: 38713052
    [TBL] [Abstract][Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.